(Pink Sheets: IDGJ),(OTCBB: ETEV), (OTCBB: PYTO), (Pink Sheets: CWRM).

RealPennies.com: Turning Pennies into dollars: (Pink Sheets: IDGJ),(OTCBB: ETEV), (OTCBB: PYTO), (Pink Sheets: CWRM).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://idgj.realpennies.com

IDGLOBAL (Pink Sheets: IDGJ) (January 7th, 2008) confirms that on the morning of December 28, 2007, its application was acknowledged and accepted by the U.S. Securities and Exchange Commission (SEC) for up-listing shares to the OTC:BB. IDGLOBAL's legal counsel, Applbaum & Zouvas LLP, completed and submitted IDGLOBAL's application to become a reporting issuer and management is encouraged and hopeful that its application will be accepted and approved in the very near future.

Daryl Regier, IDGLOBAL's President and CEO, stated, "We have worked long and hard on putting in place the reporting infrastructure and accounting procedures that comply and ensure timely release and disclosure of all information on a quarterly and annual basis as required by a reporting issuer to shareholders. It is a critical milestone to migrate our listing to a level commensurate with the sophistication of our growing investor base. Successfully completing a listing on the OTC:BB is one of several key steps IDGLOBAL is pursuing to impress upon investors a new level of credibility and visibility of disclosure."

For more info: http://etev.realpennies.com

Ethos Environmental, Inc., (OTCBB: ETEV) (January 7th, 2008) is pleased to announce that recent testing performed at PetroEcuador's Esmeraldas refinery has resulted in a more than 50 percent reduction in carbon monoxide emissions with the use of Ethos Environmental's Bunker Fuel Conditioner.

Testing was conducted and monitored by the Center for Technical and Technological Environmental Services, an independent testing agency. The analysis of the testing data complied with approved international standards.

The testing protocol consisted of the addition of Ethos Bunker Fuel Conditioner to the heavy fuel oil powering PetroEcuador's electrical generation plant at Esmeraldas. Lab reports concluded that Ethos Bunker Fuel Conditioner reduced carbon monoxide emissions from the power generation process by more than 50 percent; reductions in other toxic emissions, including a 6.94% reduction in nitros oxide (NOx), also occurred. Furthermore, use of the Ethos Bunker Fuel Conditioner improved the plant's fuel efficiency, requiring less fuel to generate the normal amount of energy.

Ethos CEO Enrique de Vilmorin, expressing pleasure with the PetroEcuador test results, stated, "[w]e're all very impressed with the results from the Esmeraldas protocol testing. I'll be returning to Ecuador in February - to complete some 2007 business, and also to sign supply contracts covering 2008 and 2009."

PetroEcuador, the state-run oil company of Ecuador, has managed the exploration, commercialization and transportation of Ecuador's petroleum resources for more than 25 years. Each month Petro-Industrial - the power generating division of PetroEcuador - consumes 16,000,000 gallons of Heavy Fuel Oil No. 6, with annual revenues exceeding $6 billion.

By significantly reducing carbon monoxide emissions, Ethos Bunker Fuel Conditioner provides a valuable pro-environment solution for industries dependent on heavy fuel oil. When added in proper concentration, the components of Ethos Bunker Fuel Conditioner improve fuel stability and also increase engine performance by cleaning and maintaining the entire fuel system.

Like the Esmeraldas power generation plant, ships burning heavy fuel oil can also benefit from the use of Ethos Bunker Fuel Conditioner. The international marine shipping fleet is a major contributor to the world's greenhouse gas emissions, as recently reported in the Wall Street Journal (Danger at Sea: Ships Draw Fire for Rising Role in Air Pollution, Nov 27, 2007). With the use of Ethos Bunker Fuel Conditioner, the potential exists for significantly reducing these emissions.

For more info: http://pyto.realpennies.com

PhytoMedical Technologies, Inc. (OTCBB: PYTO ) announced that research outcomes from ongoing in vitro studies of the Company's sponsored anti-cancer compounds have successfully demonstrated the ability to kill a strain of human brain cancer cells which is otherwise highly-resistant to currently available drugs.

Led by Dartmouth College researcher Dr. Gordon Gribble, researchers have determined that, one of several patented "bis-intercalator" anti-cancer compounds being developed by PhytoMedical has achieved a 50% or greater cancer cell kill rate at a minimum concentration in studies of the SF-295 strain of human glioblastoma (brain) cancer cells -- a significant outcome, given these brain cancer cells' drug-resistant nature.

"The outstanding results of this human cancer cell study is an extremely important step towards finding a potential solution for treating glioblastoma, an often fatal form of cancer," commented Greg Wujek, President, CEO of PhytoMedical Technologies, Inc. "The demonstrated cytotoxic effects of this unique patented compound on such a resistant strain of cancer has given us the confidence to move forward in our research and improve upon the concept of bis-intercalation and the promise it holds for the control of cancer."

In important in vitro experiments, researchers tested several variations of patented bis-intercalator compounds. These compounds have the unique capability to "intercalate" or insert their anti-cancer molecules inside DNA sites of specific cancer cells, thereby preventing the ability of the cancer cells to replicate and ultimately forcing their death.

Among several compounds tested in vitro against an often fatal strain of human glioblastoma (brain) cells, researchers have identified a high performance compound which requires the least concentration in order to achieve a 50% or greater cancer cell kill rate. This strong activity against glioblastoma cancer cells is a significant achievement given these cells' strong resistance to currently available anticancer drugs such as Lomustine, Carmustine, Nitrosourea, Hydroxyurea, and Procarbazine.

DNA is present in the nucleus of every cell of all living organisms, which are constantly dividing through a process in which the DNA in the nucleus of the original cell replicates itself to be present in the nuclei of the two new ("daughter") cells. If this replication cannot occur, the cell will die and the organism will eventually stop growing and die. Cancer is characterized by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue.

At present, anticancer molecules designed to block the replication of DNA do so through "intercalation," a mechanism in which the drug inserts itself between one set of adjacent base pairs of the DNA. PhytoMedical believes a more effective anticancer strategy is to design molecules ("bis-intercalators") that can intercalate simultaneously at two DNA sites, thus further increasing the binding between the drug and the DNA of specific cancer cells in order to stop their replication and ultimately resulting in the death of the cancer cell.

For more info: http://cwrm.realpennies.com

Cotton & Western Mining, Inc. (Pink Sheets: CWRM ) announced today that the company has received a $10,000,000.00 financial commitment from an Asian Group for the development of the company's Baja California Iron Mining Project; subject to finalization of the geological reevaluation scheduled to begin in January or February 2008.

For reasons of confidentiality, the group's name is being withheld for the time being and will be announced in a later news release.

CWRM recently acquired three (3) mixed magnetite and hematite iron mineral deposits, located in Baja California, Mexico. Outcrop chemical analysis has revealed the iron minerals to be of commercial grade suitable for concentrated fines in sizes 0.15 through 10 millimeters. Diamond bit core drilling and mine development planning are scheduled to begin in the first quarter 2008.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com